Ventyx Biosciences (VTYX) Outlook Strengthened by Cost Optimization and Positive Clinical Data

Ventyx Biosciences Inc. (NASDAQ:VTYX) is among the hottest SMID-cap stocks so far in 2025. On November 7, TheFly reported that Canaccord Genuity modestly increased its price target on the company’s stock from $14 to $16 while reiterating a Buy rating following the company’s Q3 results report a day earlier. Canaccord is now factoring in lower operating expenses in the near term, which has led to the upward revision of the target. The firm trimmed its operating cost estimates based on its analysis of the la ...